Answers are grounded in this paper and cite their sources.
Review explores molecular targeting approaches for combination immunotherapies in cancer treatment, highlighting paths to improve biomarker-driven patient selection.
Combination immunotherapy is now embedded in cancer treatment, most prominently through PD-(L)1 and CTLA-4 checkpoint blockade1. Yet patient selection has remained only partially biomarker- and ...
No takes yet. Share an insight, caveat, or question.
Sala et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: